Paolo Orsini

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Maria Menichincheri, Elena Ardini, Paola Magnaghi et al. · Journal of Medicinal Chemistry · 2016 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

R Bossi, Maria Beatrice Saccardo, Elena Ardini et al. · Biochemistry · 2010 · 167 citations

Life Sciences, Molecular Biology, Oncology +17

3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding

Paolo Pevarello, Maria Gabriella Brasca, Raffaella Amici et al. · Journal of Medicinal Chemistry · 2004 · 161 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

Gianluca Papeo, Helena Posteri, Daniela Borghi et al. · Journal of Medicinal Chemistry · 2015 · 143 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13